FOURTH AMENDMENT TO AGREEMENT
Exhibit 10.15
FOURTH AMENDMENT TO AGREEMENT
This is the fourth amendment to the Research Collaboration and License Agreement between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey (“MERCK”) and ARRIS PHARMACEUTICAL CORPORATION, a corporation organized and existing under the laws of Delaware, now known as Axys Pharmaceuticals, Inc. (“AXYS”) made as of November 6, 1996 (the “Agreement”). The purpose of this fourth amendment is to [***].
1. In accordance with the provisions of Section 2.8 and Section 5.2(d) of the Agreement and subject to MERCK’s right to terminate the Research Program and the Agreement in accordance with Section 8.2, the parties agree that [***] FTE’s will be required during the period [***] payable at an annual rate of [***] per FTE.
2. Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Agreement. The Agreement, together with the first amendment dated November 18, 1999, and this fourth amendment contain the entire understanding of the parties with respect to their subject matter. All express or implied agreements and understandings, either oral or written, heretofore made are expressly merged in and made a part of the Agreement as amended by the first, second, third and fourth amendments. All other terms and conditions of the Agreement, as amended, continue in full force and effect. The Agreement and its amendments may be amended, or any term thereof modified, only by a written instrument duly executed by both parties hereto.
IN WITNESS WHEREOF, the parties have entered into this Amendment as of March 3, 2000.
|
MERCK & CO., INC. |
|
AXYS PHARMACEUTICAL, INC. |
||
|
|
|
|
||
|
By: |
/s/ Xxxxxx Xxxxxx |
|
By: |
/s/ Xxxxxxx Xxxxxx 3/15/00 |
[***] indicates material that has been omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the Securities and Exchange Commission.
1
